FDA approves Kyprolis (carfilzomib) for combination use In the treatment of patients with relapsed multiple myeloma

Amgen has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Kyprolis® (carfilzomib) for Injection in combination with… Source link